Linda Obenauer Kutner
About Linda Obenauer Kutner
Linda Obenauer Kutner is a Senior Principal Scientist at Bristol-Myers Squibb in North Brunswick, New Jersey, with extensive experience in biotechnology and analytical techniques.
Title
Linda Obenauer Kutner holds the position of Senior Principal Scientist at Bristol-Myers Squibb. Her role involves leading key scientific initiatives and contributing to the development of advanced pharmaceutical products.
Current Role at Bristol-Myers Squibb
Linda Obenauer Kutner is currently a Senior Principal Scientist at Bristol-Myers Squibb in North Brunswick, New Jersey. She plays a pivotal role in the development of critical pharmaceuticals, including the development of OPDIVO (nivolumab, anti-PD1) and anti-PDL1 programs. Among her responsibilities are leading the analytical team and developing bioassays for release and stability.
Previous Experience at Schering-Plough Research Institute
Prior to her current role, Linda Obenauer Kutner worked at Schering-Plough Research Institute, now Merck, for 19 years from 1987 to 2006. As an Associate Principal Scientist in the Biotechnology Department, she was based in Union, New Jersey, where she gained invaluable experience and expertise in biotechnology.
Education and Expertise
Linda Obenauer Kutner earned her MA in Biology from Montclair State University, completing her studies between 1980 and 1983. She also holds a BS in Biology with a minor in Chemistry from the same institution, completed between 1976 and 1980. Her extensive knowledge base is complemented by her expertise in advanced analytical techniques such as size exclusion chromatography, capillary electrophoresis, and various microscopy techniques, including scanning electron microscopy and atomic force microscopy.
Drug Product Formulation Development
In her current role at Bristol-Myers Squibb, Linda Obenauer Kutner has played a key role in drug product formulation development studies. She conducts extended characterization, critical quality attribute (CQA) assessments, and comparability studies. Her contributions have been essential in ensuring the stability and efficacy of pharmaceutical products.